Not Signed In - Abuse Liability Study Results Of Lisdexamfetamine Dimesylate (NRP104) Presented At CPDD
Wed, 05 Jul 2006 05:00 AM EST
... Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced that results of three abuse liability studies with lisdexamfetamine dimesylate (NRP104), an investigational drug for the treatment of ADHD, were presented last week at the 68th annual meeting of the College on Problems of Drug Dependence (CPDD) in Scottsdale, AZ. [click link for full article] ...
Related Topics
- Child Abuse
- Substance Abuse
- Elder Abuse
- Child Abuse And Neglect
- Abuse
- Prescription Drugs Abuse
- Drug Abuse
- Prescription Drug Abuse
- Pregnancy and Substance Abuse
- Cocaine Abuse
- Child Maltreatment
- Sexual Abuse/assault
- Nursing Homes
- Hereditary neuropathy with liability to pressure palsies
- Radiation Studies
- Domestic Violence
- Amphetamine Abuse
- Prevention
- Sexual Abuse
- Drug Information
email this page
print this page
bookmark this page
feedback on this page
